Using the HiDO-ALZ Device to Improve Medication Management and Health Outcomes in People with Dementia

What this Trial Is About

Researchers are evaluating the HiDO-ALZ device to improve medication compliance and health outcomes in people living with dementia who need to take daily medications. This Phase II study aims to test the functionality of this automated, AI-driven medication delivery and observation platform. The device is designed to help people with dementia manage complex medication schedules, reduce caregiver burden, and support aging in place by securely dispensing medication and monitoring adherence through facial recognition and video observation. Participants will be randomly assigned to one of two groups the intervention group will use the HiDO HomeCare System HCS, which dispenses medication and verifies intake using facial recognition cameras, while the control group will continue with their standard medication management without the device. The HiDO-ALZ system provides caregivers with real-time access to medication adherence data via a web dashboard, including video logs and dose administration times. During the study, participants will be assessed at baseline and followed for 12 months with evaluations including cognitive testing such as the Alzheimers Disease Assessment Scale-Cognitive Subscale ADAS-Cog and Everyday Cognition ECog scores at multiple timepoints. Researchers will monitor medication adherence, health outcomes, and device functionality. Participants and their study partners will complete surveys, and home visits will be conducted for device installation and support. The total participation duration is 12 months with regular assessments throughout.

Preventing Medication Mismanagement in People Living With Dementia